×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AFMD – affimed n.v. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AFMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
09:31 am
afmd
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/15
09:11 am
afmd
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "hold" rating on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "hold" rating on the stock.
11/15
08:02 am
afmd
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/14
06:30 am
afmd
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Low
Report
Affimed Reports Third Quarter 2024 Financial Results & Business Update
11/6
06:30 am
afmd
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Medium
Report
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
11/5
09:00 am
afmd
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
High
Report
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
9/10
06:30 am
afmd
Affimed to Present at the Cantor Global Healthcare Conference 2024
Low
Report
Affimed to Present at the Cantor Global Healthcare Conference 2024
9/9
01:03 pm
afmd
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
07:02 am
afmd
Form 6-K Affimed N.V. For: Nov 14
Low
Report
Form 6-K Affimed N.V. For: Nov 14
10/24
02:50 pm
afmd
Form SC 13G Affimed N.V. Filed by: 683 Capital Management, LLC
Low
Report
Form SC 13G Affimed N.V. Filed by: 683 Capital Management, LLC
10/15
06:59 am
afmd
Form 6-K Affimed N.V. For: Oct 15
Low
Report
Form 6-K Affimed N.V. For: Oct 15
9/11
07:42 am
afmd
Form 6-K Affimed N.V. For: Sep 11
Low
Report
Form 6-K Affimed N.V. For: Sep 11
9/5
06:37 am
afmd
Form 6-K Affimed N.V. For: Jun 30
Low
Report
Form 6-K Affimed N.V. For: Jun 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer
27.5%
10/15 Affimed Reports Progress on Key Clinical Development Programs 10.6%
4/14 Affimed NV (NASDAQ: AFMD) had its "outperform" rating re-affirmed by analysts at SVB Leerink LLC. 8.1%
12/17 Affimed Announces Addition to NASDAQ Biotechnology Index 6.9%
8/8 Affimed NV (NASDAQ: AFMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.1%
6/12 Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland 4.7%
11/13 Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares 3.9%
11/22 Affimed NV (NASDAQ: AFMD) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. 3.3%
4/1 Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma 3.1%
8/29 Affimed NV (NASDAQ: AFMD) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 2.9%
10/15 Affimed Reports Progress on Key Clinical Development Programs 10.6%
4/14 Affimed NV (NASDAQ: AFMD) had its "outperform" rating re-affirmed by analysts at SVB Leerink LLC. 8.1%
12/17 Affimed Announces Addition to NASDAQ Biotechnology Index 6.9%
8/8 Affimed NV (NASDAQ: AFMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.1%
6/12 Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland 4.7%
11/13 Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares 3.9%
11/22 Affimed NV (NASDAQ: AFMD) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. 3.3%
4/1 Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma 3.1%
8/29 Affimed NV (NASDAQ: AFMD) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 2.9%
TOP News Decliners
11/12
Form 424B5 Affimed N.V.
-13.3%
11/7 Form 6-K Affimed N.V. For: Nov 07 -11.1%
5/22 Q1/2019 3/31/2019 EPS 0.030 ZacksConsensus -0.160 ActVsEst 0.190 - Beat -10.4%
4/28 Form 6-K Affimed N.V. For: Apr 28 -7.1%
8/9 Affimed N.V. (AFMD) Q2 2019 Earnings Call Transcript [The Motley Fool] -6.5%
3/24 Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies -5.8%
8/7 Q2/2019 6/30/2019 EPS -0.170 ZacksConsensus -0.160 ActVsEst (0.010) - Miss -4.9%
11/19 Q3/2019 9/30/2019 EPS -0.170 ZacksConsensus -0.140 ActVsEst (0.030) - Miss -4.5%
4/2 Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020 -3.5%
6/4 Affimed Announces Annual General Meeting of Shareholders -3.3%
11/7 Form 6-K Affimed N.V. For: Nov 07 -11.1%
5/22 Q1/2019 3/31/2019 EPS 0.030 ZacksConsensus -0.160 ActVsEst 0.190 - Beat -10.4%
4/28 Form 6-K Affimed N.V. For: Apr 28 -7.1%
8/9 Affimed N.V. (AFMD) Q2 2019 Earnings Call Transcript [The Motley Fool] -6.5%
3/24 Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies -5.8%
8/7 Q2/2019 6/30/2019 EPS -0.170 ZacksConsensus -0.160 ActVsEst (0.010) - Miss -4.9%
11/19 Q3/2019 9/30/2019 EPS -0.170 ZacksConsensus -0.140 ActVsEst (0.030) - Miss -4.5%
4/2 Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020 -3.5%
6/4 Affimed Announces Annual General Meeting of Shareholders -3.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: